PsilodexMedication × psilocybin
Your list , 0 items
Medication class

Tricyclic antidepressants and psilocybin.

11 records in this group. 4 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

11Records
4With human data

Overview

Reviewed 2026-10-18

Tricyclic antidepressants block reuptake of noradrenaline and, to varying degrees, serotonin, and several also block 5-HT2A, the serotonin receptor psilocybin acts on. No controlled study has combined a tricyclic with psilocybin. With LSD, long-term imipramine, desipramine or clomipramine intensified the response in all 5 people who completed questionnaires (Bonson & Murphy 1996), the opposite of what 5-HT2A blockade alone would predict. Nortriptyline appears in one multi-drug case report in which psilocybin mushrooms, taken with phenelzine and other medications, produced no noticeable subjective effects (Barnett 2024).

Tricyclics have been reported to cause irregular heart rhythms, a fast heart rate and slowed cardiac conduction. The amitriptyline label also describes seizures, a drop in blood pressure on standing, and anticholinergic effects (such as dry mouth and a fast heart rate). After prolonged use, stopping suddenly can cause nausea, headache and malaise (amitriptyline prescribing information). Psilocybin has been shown to raise heart rate and blood pressure in some healthy adults (Becker 2022).

Low-dose doxepin, a tricyclic, is also used for sleep and appears on the sleep medications page. Amoxapine has dopamine-blocking activity; Colorado's rule names antipsychotic medications without defining the term, so whether it covers amoxapine is unsettled, and its record explains why.

Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.

Also searched as tricyclic · TCA · tricyclics

01 What the evidence covers

Best evidence available per medication
1Case reports
Case reports or online surveys
3Other psychedelic
Human data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text
7No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • Amitriptyline · ElavilEvidence: No psilocybin data

    Depression

    Not studied with psilocybin; related drugs strengthened LSD's effects. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Amoxapine · AsendinEvidence: No psilocybin data

    Depression, including depression with anxiety or agitation

    It blocks the receptor psilocybin works through, so it may weaken psilocybin, though related drugs strengthened LSD's effects.

    CO: unsettled · OR: not mentioned in rule · NM: rules not final

  • Clomipramine · AnafranilEvidence: Other psychedelic

    Obsessive-compulsive disorder (OCD)

    It may weaken psilocybin, yet 5 people on it or related drugs had stronger LSD responses. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Desipramine · NorpraminEvidence: Other psychedelic

    Depression

    Its effect on psilocybin is unknown; with LSD, all 5 people on such antidepressants had stronger responses. Also, it raises blood pressure and heart rate.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Dothiepin / dosulepin · ProthiadenEvidence: No psilocybin data

    Psychotropics

    With LSD, long-term tricyclic use strengthened responses, so it may strengthen psilocybin (not studied). Also, it carries heart-rhythm and seizure risks.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Doxepin · Sinequan, SilenorEvidence: No psilocybin data

    Depression; Anxiety

    In theory it blunts psilocybin, but related tricyclics strengthened LSD responses. Also, it sedates and affects heart rhythm; 3–6 mg acts mainly as an antihistamine.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Imipramine · TofranilEvidence: Other psychedelic

    Depression; Bedwetting in children (short-term add-on)

    Its effect on psilocybin is unclear; with LSD, it or similar drugs increased the response in all 5 people interviewed.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Lofepramine · GamanilEvidence: No psilocybin data

    Psychotropics

    In a small LSD study, related tricyclics increased the response, so it may strengthen psilocybin. Also, it can affect heart rhythm and lower seizure threshold.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Nortriptyline · PamelorEvidence: Case reports

    Depression

    In one case, psilocybin had no noticeable effect when taken with nortriptyline plus phenelzine. Also, it can affect heart rhythm and seizure threshold.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Protriptyline · VivactilEvidence: No psilocybin data

    Depression

    Related tricyclic drugs increased LSD's effects, so it is expected to intensify psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Trimipramine · SurmontilEvidence: No psilocybin data

    Depression

    In lab studies it binds strongly to psilocybin's receptor, so it may weaken psilocybin. Also, it can affect heart rhythm and seizure risk.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
11Anticholinergic
11Lowers seizure threshold or carries seizure risk
11Psychiatric reactions
11QT-prolonging
11Withdrawal or rebound if stopped abruptly
10Lowers blood pressure or causes orthostasis
9Serotonergic
8Sedating or CNS depressant
5Raises blood pressure or heart rate
3Blocks 5-HT2A (may blunt effects)
3Dehydration or electrolyte risk

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

No provision names these medications or this group. 1 unsettled.

Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” without defining the term or limiting it by indication, so whether it covers this medication is unsettled; the regulator has not addressed this. Amoxapine is an antidepressant approved for depression, but it and its metabolites block dopamine D2 receptors, as antipsychotics do, and its label describes neuroleptic malignant syndrome and tardive dyskinesia. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent.

Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 10 of the 11 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
9Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233.
3Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436.
1Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
1Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008;22(6):603–620.
1Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.

Related classes

Records reviewed 2026-10-14 to 2026-10-25. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25